14.10.20: Not intended for U.S. and UK Media
Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's LymphomaPhase III study CHRONOS-3 in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have received one or more lines of prior treatment meets primary endpoint / Safety and tolerability observed in the trial were generally consistent with previously published data on the individual components of the combination and no new safety signals were identified / Copanlisib is already approved in the U.S. under accelerated approval based on overall response rate (ORR) of 104 adu...
Source: Bayer IR Newsfeed: Events - October 14, 2020 Category: Pharmaceuticals Source Type: news

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... Biopharmaceuticals, Oncology, Regulatory Innovent Biologics, Eli Lilly, HALPRYZA, rituximab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 9, 2020 Category: Pharmaceuticals Source Type: news

Novel Radioimmunotherapy Reverses Resistance to Commonly Used Lymphoma Drug
(Society of Nuclear Medicine and Molecular Imaging) A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine. When used in combination with rituximab, 177Lu-lilotomab-satetraxetan was shown to substantially increase rituximab binding and rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) activity, resulting in significant tumor growth delay in a non-Hodgkin's lymphoma mouse model. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Increased Risk of Severe COVID With Anti-B-Cell MS Drugs? Increased Risk of Severe COVID With Anti-B-Cell MS Drugs?
Concerns raised over an increased risk of severe COVID-19 outcomes in MS patients on anti-CD20 B-cell depleting drugs such as ocrelizumab and rituximab following presentation of new data.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 29, 2020 Category: Pathology Tags: Neurology & Neurosurgery News Source Type: news

Late-Onset Neutropenia Common in Patients on Rituximab Late-Onset Neutropenia Common in Patients on Rituximab
"Even though most [cases] are incidental and can be self-limiting, some can be severe and associated with sepsis."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 22, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Lower Rituximab Dose as Effective, Safer in MS Lower Rituximab Dose as Effective, Safer in MS
Further data suggest that a lower dose of rituximab may offer similar effectiveness with a better safety profile than a higher dose commonly used.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 18, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Disseminated Enterovirus Infection With Rituximab/Ibrutinib Disseminated Enterovirus Infection With Rituximab/Ibrutinib
This case underscores the risk for severe and potentially life-threatening immune-related side effects with combined therapy with rituximab and ibrutinib.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

In MS, Serious AEs More Common in Rituximab vs Ocrelizumab In MS, Serious AEs More Common in Rituximab vs Ocrelizumab
Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 11, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Lowering Rituximab Dose in Patients With MS Safe, Effective Lowering Rituximab Dose in Patients With MS Safe, Effective
A new study has found that reducing rituximab dosage from 1,000 mg every 6 months to 500 mg every 6 months is a safe and stable choice for patients with multiple sclerosis.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 10, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

RA Infection Risk With Abatacept, Rituximab and Tocilizumab RA Infection Risk With Abatacept, Rituximab and Tocilizumab
How common are infections among rheumatoid arthritis patients receiving treatment with these non-TNF-inhibitors?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Binding mechanisms of therapeutic antibodies to human CD20
Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20) constitute important immunotherapies for the treatment of B cell malignancies and autoimmune diseases. Type I and II therapeutic mAbs differ in B cell binding properties and cytotoxic effects, reflecting differential interaction mechanisms with CD20. Here we present 3.7- to 4.7-angstrom cryo–electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. The structures and binding thermodynamics demonstrate that upon binding to CD20, type II mAbs form te...
Source: ScienceNOW - August 12, 2020 Category: Science Authors: Kumar, A., Planchais, C., Fronzes, R., Mouquet, H., Reyes, N. Tags: Biochemistry, Medicine, Diseases r-articles Source Type: news

Cladribine With Concurrent or Delayed Rituximab in HCL Cladribine With Concurrent or Delayed Rituximab in HCL
Could the addition of rituximab to cladribine treatment help clear minimal residual disease in patients with hairy cell leukemia?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Isolated IgG4-Related Hypophysitis Treated With Rituximab Isolated IgG4-Related Hypophysitis Treated With Rituximab
Is rituximab a safe and effective treatment option for IgG4-related hypophysitis?Journal of the Endocrine Society (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 30, 2020 Category: Intensive Care Tags: Diabetes & Endocrinology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news